B6.Cg-Ptprca Trp53inp1tm1Acar/Orl

Status

Available to order

EMMA IDEM:06223
Citation informationRRID:IMSR_EM:06223 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

 
International strain nameB6.Cg-Ptprca Trp53inp1tm1Acar/Orl
Alternative nameTP53INP1 KO Ly5.1
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolTrp53inp1tm1Acar, Ptprca
Gene/Transgene symbolTrp53inp1, Ptprc

Information from provider

ProviderAlice Carrier
Provider affiliationInserm U1068 / CRCM
Genetic informationNull mutation of Trp53inp1 gene.
Phenotypic informationMouse model of chronic oxidative stress promoting cancer development.
Breeding historyWe already described the breeding history in our previous submissions of this KO mutation on C57BL/6 and 129/Sv background (EMMA strain ID EM:02038). For the present submission on Ly5.1 (Ptprca, or CD45 Ly5.1 allele), we have crossed homozygous KO on C57BL/6 (Ly5.2) background with wild-type Ly5.1 mice to obtain homozygous KO Ly5.1 in two steps. Those mice are mandatory to perform competitive bone-marrow reconstitution experiments.
References
  • Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1.;Gommeaux Julien, Cano Carla, Garcia Stéphane, Gironella Meritxell, Pietri Sylvia, Culcasi Marcel, Pébusque Marie-Josèphe, Malissen Bernard, Dusetti Nelson, Iovanna Juan, Carrier Alice, ;2007;Molecular and cellular biology;27;2215-28; 17242209
  • Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.;Gironella Meritxell, Seux Mylène, Xie Min-Jue, Cano Carla, Tomasini Richard, Gommeaux Julien, Garcia Stephane, Nowak Jonathan, Yeung Man Lung, Jeang Kuan-Teh, Chaix Amandine, Fazli Ladan, Motoo Yoshiharu, Wang Qing, Rocchi Palma, Russo Antonio, Gleave Martin, Dagorn Jean-Charles, Iovanna Juan L, Carrier Alice, Pébusque Marie-Josèphe, Dusetti Nelson J, ;2007;Proceedings of the National Academy of Sciences of the United States of America;104;16170-5; 17911264
  • Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function.;Cano Carla E, Gommeaux Julien, Pietri Sylvia, Culcasi Marcel, Garcia Stéphane, Seux Mylène, Barelier Sarah, Vasseur Sophie, Spoto Rose P, Pébusque Marie-Josèphe, Dusetti Nelson J, Iovanna Juan L, Carrier Alice, ;2009;Cancer research;69;219-26; 19118006
  • Mutant mouse models of oxidative stress.;Pouyet Laurent, Carrier Alice, ;2010;Transgenic research;19;155-64; 19662508
  • TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression.;Seux M, Peuget S, Montero M P, Siret C, Rigot V, Clerc P, Gigoux V, Pellegrino E, Pouyet L, N'Guessan P, Garcia S, Dufresne M, Iovanna J L, Carrier A, André F, Dusetti N J, ;2011;Oncogene;30;3049-61; 21339733
  • Absence of tumor suppressor tumor protein 53-induced nuclear protein 1 (TP53INP1) sensitizes mouse thymocytes and embryonic fibroblasts to redox-driven apoptosis.;N'guessan Prudence, Pouyet Laurent, Gosset Gaëlle, Hamlaoui Sonia, Seillier Marion, Cano Carla E, Seux Mylène, Stocker Pierre, Culcasi Marcel, Iovanna Juan L, Dusetti Nelson J, Pietri Sylvia, Carrier Alice, ;2011;Antioxidants & redox signaling;15;1639-53; 21235351
  • TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death.;Seillier M, Peuget S, Gayet O, Gauthier C, N'Guessan P, Monte M, Carrier A, Iovanna J L, Dusetti N J, ;2012;Cell death and differentiation;19;1525-35; 22421968
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreInstitut de Transgenose, INTRAGENE, Orléans, France
Animals used for archivinghomozygous C57BL/6J males, homozygous C57BL/6J females
Breeding at archiving centreTo restore the right phenotype with the frozen sperm users should use C57BL/6-Ly5.1 (Ptprc-a) females for the IVF. Embryos have been obtained crossing males and females of the Trp53inp1-KO L5.1 (Ptprc-a) line so they all have the right genotype.

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

MGI phenotypes (allele matching)
  • abnormal cell morphology / MGI
  • abnormal crypts of Lieberkuhn morphology / MGI
  • abnormal intestinal mucosa morphology / MGI
  • increased body weight / MGI
  • hyperglycemia / MGI
  • neoplasm / MGI
  • increased colonic adenoma incidence / MGI
  • increased circulating insulin level / MGI
  • hepatic steatosis / MGI
  • increased liver weight / MGI
  • large intestinal inflammation / MGI
  • oxidative stress / MGI
  • increased incidence of tumors by chemical induction / MGI
  • impaired glucose tolerance / MGI
  • insulin resistance / MGI
  • increased susceptibility to weight gain / MGI
  • increased susceptibility to diet-induced obesity / MGI
  • abnormal mitochondrion morphology / MGI
  • abnormal mitochondrial physiology / MGI
  • abnormal epididymal fat pad morphology / MGI
  • increased susceptibility to induced colitis / MGI
  • abnormal renal fat pad morphology / MGI
  • increased sensitivity to xenobiotic induced morbidity/mortality / MGI
  • abnormal respiratory electron transport chain / MGI
  • abnormal oxidative phosphorylation / MGI
  • increased mitochondria number / MGI
  • abnormal mitophagy / MGI
  • increased body fat mass / MGI
  • increased susceptibility to diet-induced non-insulin dependent diabetes / MGI
MGI phenotypes (gene matching)
  • abnormal long bone metaphysis morphology / MGI
  • abnormal leukocyte cell number / MGI
  • increased neutrophil cell number / MGI
  • decreased leukocyte cell number / MGI
  • extramedullary hematopoiesis / MGI
  • abnormal erythropoiesis / MGI
  • enlarged spleen / MGI
  • spleen hyperplasia / MGI
  • enlarged lymph nodes / MGI
  • decreased thymocyte number / MGI
  • abnormal immune system cell morphology / MGI
  • abnormal myelination / MGI
  • abnormal oligodendrocyte morphology / MGI
  • abnormal osteoclast physiology / MGI
  • abnormal digestion / MGI
  • abnormal immune system physiology / MGI
  • abnormal humoral immune response / MGI
  • thymus hypoplasia / MGI
  • arrested T cell differentiation / MGI
  • abnormal T cell activation / MGI
  • liver inflammation / MGI
  • lung inflammation / MGI
  • premature death / MGI
  • abnormal T cell differentiation / MGI
  • no abnormal phenotype detected / MGI
  • abnormal bone marrow cell morphology/development / MGI
  • abnormal lymphopoiesis / MGI
  • abnormal double-positive T cell morphology / MGI
  • increased susceptibility to viral infection / MGI
  • abnormal T cell physiology / MGI
  • abnormal B cell number / MGI
  • increased IgA level / MGI
  • abnormal immune system organ morphology / MGI
  • glomerulonephritis / MGI
  • increased urine protein level / MGI
  • abnormal cytokine secretion / MGI
  • no phenotypic analysis / MGI
  • kidney failure / MGI
  • oliguria / MGI
  • abnormal thymocyte activation / MGI
  • abnormal T cell subpopulation ratio / MGI
  • increased anti-double stranded DNA antibody level / MGI
  • abnormal T cell selection / MGI
  • abnormal positive T cell selection / MGI
  • increased B-1 B cell number / MGI
  • abnormal osteoclast morphology / MGI
  • increased B cell number / MGI
  • increased T cell number / MGI
  • decreased B cell number / MGI
  • decreased T cell number / MGI
  • abnormal response to infection / MGI
  • diarrhea / MGI
  • decreased cytotoxic T cell cytolysis / MGI
  • increased double-negative T cell number / MGI
  • decreased double-positive T cell number / MGI
  • decreased B cell proliferation / MGI
  • decreased T cell proliferation / MGI
  • increased susceptibility to autoimmune disorder / MGI
  • immune system phenotype / MGI
  • hematopoietic system phenotype / MGI
  • decreased susceptibility to type I hypersensitivity reaction / MGI
  • CNS inflammation / MGI
  • increased T cell apoptosis / MGI
  • abnormal T cell morphology / MGI
  • increased NK cell number / MGI
  • abnormal memory T cell number / MGI
  • increased memory T cell number / MGI
  • decreased memory T cell number / MGI
  • absent T cells / MGI
  • decreased CD4-positive, alpha beta T cell number / MGI
  • abnormal CD4-positive T cell differentiation / MGI
  • decreased CD8-positive, alpha-beta T cell number / MGI
  • abnormal CD8-positive, alpha-beta T cell differentiation / MGI
  • increased single-positive T cell number / MGI
  • decreased single-positive T cell number / MGI
  • increased plasma cell number / MGI
  • lymph node hyperplasia / MGI
  • abnormal granulocyte differentiation / MGI
  • increased dendritic cell number / MGI
  • decreased B-1a cell number / MGI
  • increased B-1b cell number / MGI
  • decreased B-1b cell number / MGI
  • decreased follicular B cell number / MGI
  • increased transitional stage B cell number / MGI
  • abnormal follicular B cell physiology / MGI
  • decreased B-2 B cell number / MGI
  • decreased mature B cell number / MGI
  • abnormal B cell activation / MGI
  • abnormal leukocyte morphology / MGI
  • decreased gamma-delta intraepithelial T cell number / MGI
  • abnormal CD4-positive, alpha-beta intraepithelial T cell morphology / MGI
  • increased spleen red pulp amount / MGI
  • increased spleen white pulp amount / MGI
  • increased IgG2a level / MGI
  • increased plasmacytoid dendritic cell number / MGI
  • abnormal chemokine secretion / MGI
  • decreased memory B cell number / MGI
  • decreased mast cell degranulation / MGI
  • abnormal intraepithelial T cell morphology / MGI
  • abnormal intraepithelial T cell number / MGI
  • decreased oligodendrocyte number / MGI
  • increased DN3 thymocyte number / MGI
  • decreased DN4 thymocyte number / MGI
  • abnormal NK cell physiology / MGI
  • mortality/aging / MGI
  • decreased CD4-positive, alpha-beta memory T cell number / MGI
  • decreased CD8-positive, alpha-beta memory T cell number / MGI
  • lethality at weaning, incomplete penetrance / MGI
  • increased alpha-beta T cell number / MGI
  • decreased CD8-positive, naive alpha-beta T cell number / MGI
  • abnormal cell morphology / MGI
  • abnormal crypts of Lieberkuhn morphology / MGI
  • abnormal intestinal mucosa morphology / MGI
  • increased body weight / MGI
  • hyperglycemia / MGI
  • neoplasm / MGI
  • increased colon adenoma incidence / MGI
  • increased circulating insulin level / MGI
  • hepatic steatosis / MGI
  • increased liver weight / MGI
  • large intestinal inflammation / MGI
  • oxidative stress / MGI
  • increased incidence of tumors by chemical induction / MGI
  • impaired glucose tolerance / MGI
  • insulin resistance / MGI
  • increased susceptibility to weight gain / MGI
  • increased susceptibility to diet-induced obesity / MGI
  • abnormal mitochondrion morphology / MGI
  • abnormal mitochondrial physiology / MGI
  • abnormal epididymal fat pad morphology / MGI
  • increased susceptibility to induced colitis / MGI
  • abnormal renal fat pad morphology / MGI
  • increased sensitivity to xenobiotic induced morbidity/mortality / MGI
  • abnormal respiratory electron transport chain / MGI
  • abnormal oxidative phosphorylation / MGI
  • increased mitochondria number / MGI
  • abnormal mitophagy / MGI
  • increased body fat mass / MGI
  • increased susceptibility to diet-induced non-insulin dependent diabetes / MGI

Literature references

  • Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1.;Gommeaux Julien, Cano Carla, Garcia Stéphane, Gironella Meritxell, Pietri Sylvia, Culcasi Marcel, Pébusque Marie-Josèphe, Malissen Bernard, Dusetti Nelson, Iovanna Juan, Carrier Alice, ;2007;Molecular and cellular biology;27;2215-28; 17242209
  • Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.;Gironella Meritxell, Seux Mylène, Xie Min-Jue, Cano Carla, Tomasini Richard, Gommeaux Julien, Garcia Stephane, Nowak Jonathan, Yeung Man Lung, Jeang Kuan-Teh, Chaix Amandine, Fazli Ladan, Motoo Yoshiharu, Wang Qing, Rocchi Palma, Russo Antonio, Gleave Martin, Dagorn Jean-Charles, Iovanna Juan L, Carrier Alice, Pébusque Marie-Josèphe, Dusetti Nelson J, ;2007;Proceedings of the National Academy of Sciences of the United States of America;104;16170-5; 17911264
  • Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function.;Cano Carla E, Gommeaux Julien, Pietri Sylvia, Culcasi Marcel, Garcia Stéphane, Seux Mylène, Barelier Sarah, Vasseur Sophie, Spoto Rose P, Pébusque Marie-Josèphe, Dusetti Nelson J, Iovanna Juan L, Carrier Alice, ;2009;Cancer research;69;219-26; 19118006
  • Mutant mouse models of oxidative stress.;Pouyet Laurent, Carrier Alice, ;2010;Transgenic research;19;155-64; 19662508
  • TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression.;Seux M, Peuget S, Montero M P, Siret C, Rigot V, Clerc P, Gigoux V, Pellegrino E, Pouyet L, N'Guessan P, Garcia S, Dufresne M, Iovanna J L, Carrier A, André F, Dusetti N J, ;2011;Oncogene;30;3049-61; 21339733
  • Absence of tumor suppressor tumor protein 53-induced nuclear protein 1 (TP53INP1) sensitizes mouse thymocytes and embryonic fibroblasts to redox-driven apoptosis.;N'guessan Prudence, Pouyet Laurent, Gosset Gaëlle, Hamlaoui Sonia, Seillier Marion, Cano Carla E, Seux Mylène, Stocker Pierre, Culcasi Marcel, Iovanna Juan L, Dusetti Nelson J, Pietri Sylvia, Carrier Alice, ;2011;Antioxidants & redox signaling;15;1639-53; 21235351
  • TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death.;Seillier M, Peuget S, Gayet O, Gauthier C, N'Guessan P, Monte M, Carrier A, Iovanna J L, Dusetti N J, ;2012;Cell death and differentiation;19;1525-35; 22421968

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).